does glp 1 cause depression Insights into a possible role of glucagon-like peptide-1 receptor agonists in the treatment of | Pharmacological Reports Your Brain on GLP-1s: What

L-carnitine is not gender-specific

Oxidative stress and neurodegeneration: insights and therapeutic strategies for parkinsons disease

GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) and the GIP/GLP-1 dual agonist tirzepatide were studied in STEP (semaglutide, weight management, NEJM 2021), SURMOUNT (tirzepatide, weight management, NEJM 2022), and SURMOUNT-OSA (tirzepatide, obstructive sleep apnea, NEJM 2024)

Novo says the breadth of the advertising campaign is causing competitive harm and the false superiority messages are reaching a large, ever-growing audience of prospective patients. Novo Nordisk Says Lillys Ad Is No Longer Accurate Novo Nordisks lawsuit cites a study that shows its higher 7.2 milligram dose of Wegovy, approved by the FDA in March, helps patients lose an average of 47 pounds, while one in three participants lost about 62 pounds